Dr. Kramer has a background in radiochemistry, tracer development, and PET Imaging and received his PhD in Radiopharmaceutical Chemistry from Johannes Gutenberg University Mainz, Germany in 2012. His main research interest is focused on tracer development for CNS receptor imaging and the application of 68Ga- & 177Lu-labelled Theranostics for diagnosis and treatment in oncology. He joined Positronpharma SA and the nuclear medicine & PET facility Positronmed in 2012 where he is responsible for research and development.